Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lorazepam
Drug ID BADD_D01318
Description Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
Indications and Usage Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
Marketing Status approved
ATC Code N05BA06
DrugBank ID DB00186
KEGG ID D00365
MeSH ID D008140
PubChem ID 3958
TTD Drug ID D0E0OG
NDC Product Code 0641-6047; 0641-6049; 0904-6008; 71554-009; 72166-001; 0093-3426; 0121-0770; 52427-663; 55154-7976; 60687-638; 65162-018; 68788-7533; 69315-904; 70518-0275; 70518-0445; 0641-6002; 0641-6048; 72789-236; 76329-8261; 0904-6007; 51927-0195; 67763-101; 76420-296; 0093-3427; 52427-661; 61919-062; 63187-536; 67296-1478; 67296-1622; 68071-5022; 0409-6778; 71205-235; 71335-1467; 71610-600; 72572-380; 0641-6000; 0641-6001; 0641-6003; 0641-6051; 48087-0076; 51927-1005; 55154-7975; 61919-607; 67296-1332; 67544-142; 71610-008; 71610-654; 71610-655; 58118-1095; 63304-773; 65162-687; 68071-4916; 68071-5250; 70518-0486; 70518-2186; 70518-2442; 71205-228; 71335-0329; 71335-1455; 71335-1694; 0641-6207; 57218-950; 0187-0064; 53002-5291; 58118-0904; 60760-516; 63187-576; 68071-2666; 70934-782; 72789-197; 72789-226; 0904-6009; 13107-085; 0187-0065; 50383-705; 54348-049; 60687-627; 60687-649; 63304-774; 65162-015; 71335-1138; 71610-255; 12828-0025; 0093-3425; 53002-6290; 67544-191; 68071-3096; 0409-1985; 68788-7355; 70518-1275; 70518-3188; 70518-3423; 71205-166; 71205-756; 71610-122; 71610-229; 71610-674; 0641-6044; 0641-6046; 0641-6050; 64330-020; 43353-255; 52427-658; 55154-7977; 63304-772; 68788-7428; 69315-906; 70518-2268; 70518-3225; 72189-351; 17478-040; 52427-667; 55700-778; 65162-017; 67544-261; 70518-1520; 0054-3532; 71335-0655; 49452-4140; 51552-0729; 13107-083; 50090-5508; 63629-2953; 68071-2662; 68071-3121; 68071-5068; 69315-905; 71610-178; 71610-199; 71610-225; 0641-6045; 52696-0002; 62991-1682; 13107-084; 45865-499; 0187-0063; 50090-5509; 58118-1096
UNII O26FZP769L
Synonyms Lorazepam | Ativan | Orfidal Wyeth | Wyeth, Orfidal | Témesta | Tolid | Donix | Duralozam | Durazolam | Idalprem | Laubeel | Lorazep Von Ct | Von Ct, Lorazep | Lorazepam Medical | Medical, Lorazepam | Lorazepam-Neuraxpharm | Lorazepam Neuraxpharm | Lorazepam-Ratiopharm | Lorazepam Ratiopharm | Novo-Lorazem | Novo Lorazem | Nu-Loraz | Nu Loraz | Sedicepan | Sinestron | WY-4036 | WY 4036 | WY4036 | Apo-Lorazepam | Apo Lorazepam | Somagerol | Temesta
Chemical Information
Molecular Formula C15H10Cl2N2O2
CAS Registry Number 846-49-1
SMILES C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral disorder17.02.10.0170.000062%Not Available
Faecaloma07.01.03.0040.000046%Not Available
Pulmonary mass22.02.07.0040.000068%Not Available
Anxiety disorder19.06.01.002--Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000397%
Major depression19.15.01.0030.000077%Not Available
Myoglobinaemia15.05.03.028; 02.04.02.0280.000031%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.000046%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.001--
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000031%Not Available
Feeding disorder19.09.01.003; 14.03.02.003--Not Available
Gastrointestinal motility disorder07.02.03.0010.000031%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Limb discomfort15.03.04.014--Not Available
Mental disorder19.07.01.0020.000166%Not Available
Partial seizures17.12.03.0100.000031%Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Abnormal behaviour19.01.01.0010.000296%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Psychiatric symptom19.01.02.001--Not Available
Adverse drug reaction08.06.01.009--Not Available
Disease recurrence08.01.03.050--Not Available
Obstructive airways disorder22.03.01.011--Not Available
Pancreatic neoplasm16.13.11.005; 07.21.09.0040.000031%Not Available
Psychotic disorder19.03.01.0020.000283%
Pulmonary function test decreased13.19.01.001--Not Available
The 14th Page    First    Pre   14 15 16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene